X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
AJANTA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,818368-   
Low Rs1,106265-   
Sales per share (Unadj.) Rs239.5109.3-  
Earnings per share (Unadj.) Rs52.8-27.6-  
Cash flow per share (Unadj.) Rs59.5-22.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.085.8-  
Shares outstanding (eoy) m88.77168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.12.9 211.0%   
Avg P/E ratio x27.7-11.5 -241.2%  
P/CF ratio (eoy) x24.6-13.9 -177.3%  
Price / Book Value ratio x6.43.7 172.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,78253,397 243.1%   
No. of employees `0006.84.3 158.3%   
Total wages/salary Rs m3,7653,351 112.3%   
Avg. sales/employee Rs Th3,128.44,298.8 72.8%   
Avg. wages/employee Rs Th554.0780.6 71.0%   
Avg. net profit/employee Rs Th689.7-1,083.2 -63.7%   
INCOME DATA
Net Sales Rs m21,25818,455 115.2%  
Other income Rs m242129 186.9%   
Total revenues Rs m21,49918,584 115.7%   
Gross profit Rs m6,584-3,198 -205.9%  
Depreciation Rs m596796 74.8%   
Interest Rs m4500 0.8%   
Profit before tax Rs m6,226-4,365 -142.6%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539273 564.3%   
Profit after tax Rs m4,686-4,650 -100.8%  
Gross profit margin %31.0-17.3 -178.7%  
Effective tax rate %24.7-6.2 -395.7%   
Net profit margin %22.0-25.2 -87.5%  
BALANCE SHEET DATA
Current assets Rs m12,23613,517 90.5%   
Current liabilities Rs m3,4617,605 45.5%   
Net working cap to sales %41.332.0 128.9%  
Current ratio x3.51.8 198.9%  
Inventory Days Days60111 54.3%  
Debtors Days Days84124 68.2%  
Net fixed assets Rs m11,1407,879 141.4%   
Share capital Rs m17786 206.5%   
"Free" reserves Rs m20,2370-   
Net worth Rs m20,41414,485 140.9%   
Long term debt Rs m105,090 0.2%   
Total assets Rs m24,48627,363 89.5%  
Interest coverage x1,519.4-7.7 -19,650.4%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.7 128.7%   
Return on assets %19.2-15.2 -126.3%  
Return on equity %23.0-32.1 -71.5%  
Return on capital %30.5-19.8 -154.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,0520-   
CASH FLOW
From Operations Rs m2,8541,575 181.2%  
From Investments Rs m-2,604-484 538.4%  
From Financial Activity Rs m-24,620 -0.0%  
Net Cashflow Rs m2485,711 4.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.07 Rs / ZAR

Compare AJANTA PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  PANACEA BIOTECH  SUVEN LIFE  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS